Sandy Cove Advisors’s scPharmaceuticals SCPH Stock Holding History

Sandy Cove Advisors’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,592	Closed	-$37.5K	–	126
2024 Q4	$37.5K	Hold	10,592	–	–	0.01%	125
2024 Q3	$48.3K	Hold	10,592	–	–	0.02%	124
2024 Q2	$46.1K	Hold	10,592	–	–	0.02%	111
2024 Q1	$53.2K	Hold	10,592	–	–	0.02%	121
2023 Q4	$66.4K	Hold	10,592	–	–	0.03%	120
2023 Q3	$75.4K	Hold	10,592	–	–	0.04%	116
2023 Q2	$108K	Hold	10,592	–	–	0.06%	121
2023 Q1	$96.1K	Hold	10,592	–	–	0.07%	88
2022 Q4	$75.9K	Hold	10,592	–	–	0.06%	80
2022 Q3	$69K	Hold	10,592	–	–	0.06%	75
2022 Q2	$51K	Hold	10,592	–	–	0.05%	76
2022 Q1	$60K	Hold	10,592	–	–	0.05%	174
2021 Q4	$53K	Buy	+10,592	New	+$58.3K	0.04%	186

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Sandy Cove Advisors's SCPH Position: Q1 2025 in Review

Sandy Cove Advisors sold out of scPharmaceuticals (SCPH) in Q1 2025, closing a stake of 10,592 shares — an estimated $37.5K sold.

Sandy Cove Advisors first reported a position in SCPH in Q4 2021 and held it in 13 quarters. The position peaked at $108K in Q2 2023. 88 funds tracked by Wall St. Rank hold SCPH as of Q1 2025.

Sandy Cove Advisors reported no remaining scPharmaceuticals position as of Q1 2025 after selling out during the quarter.
Sandy Cove Advisors sold 10,592 scPharmaceuticals shares in Q1 2025, an estimated $37.5K.
Sandy Cove Advisors first reported a position in scPharmaceuticals in Q4 2021 and held it in 13 quarters.
Sandy Cove Advisors's scPharmaceuticals position peaked at $108K in Q2 2023.
88 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2025.

Based on Sandy Cove Advisors's 13F filing for Q1 2025, filed 12 May 2025.